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Abstract
Bevacizumab (Bv) remains frequently prescribed in glioblastoma (GBM) patients, especially at recurrence. We conducted 
a prospective clinical trial with 29 recurrent GBM patients treated with Bv alone with a longitudinal follow-up of different 
circulating immune cells [complete blood count, myeloid-derived suppressor cells (MDSCs), classical, intermediate, non-
classical and Tie2 monocytes, VEGFR1+ and regulatory T cells (Treg)]. We observed a significant increase for leucocytes, 
neutrophils, eosinophils and classical monocytes and a decrease for the fraction of Treg during the treatment. The best 
prognostic values for survival under Bv were obtained for basal neutrophils and Treg. Counts below 3.9 G/L for neutrophils 
and above 0.011 G/L for Treg were associated with an overall survival of 17.5 and 19.9 months, respectively, as compared 
with 5.4 and 5.6 months, respectively, for counts above and below these cutoffs (p = 0.004 and p < 0.001). No prognostic 
impact was observed for neutrophils in a retrospective cohort of 26 patients treated with nitrosoureas alone. In another 
retrospective validation cohort of 61 GBM patients treated at recurrence with a Bv-containing regimen, an interaction was 
observed between neutrophils and corticosteroid intake. The predictive value of neutrophils on survival under Bv was lost in 
patients treated with corticosteroids, when steroid-free patients with a low neutrophil count had a particularly long median 
survival of 3.4 years. These two simply accessible criteria (basal neutrophils and steroid intake) could be used to reserve this 
relatively costly treatment for patients likely to be the most responsive to Bv and prevent unnecessary side effects in others.
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Treg  Regulatory T cells
VEGF  Vascular endothelial growth factor
Introduction
The standard of care for glioblastoma (GBM) patients at 
recurrence is not well defined. Bevacizumab (Bv) is often 
prescribed in various countries because two phase II stud-
ies initially showed that approximately 30% of patients 
responded to treatment, with improved progression-free 
survival (PFS) [1, 2]. This led to the randomised controlled 
phase II BELOB trial, in which the rate of overall survival 
at 9 and 12 months was higher with the combination of Bv 
and lomustine than with either agent alone [3]. Yet, in the 
large EORTC 26101 phase 3 trial, adding Bv to lomustine 
failed to increase survival over lomustine alone, although 
the PFS was longer (4.2 months) in the combination group 
than in the monotherapy group (1.5 months) [4]. Despite 
these mixed results, Bv remains a therapeutic option for 
GBM patients. This is explained, in part, by the fact that 
this treatment can have corticosteroid-sparing effects, 
but also because a proportion of patients show long-term 
response to Bv. Several attempts have been made to iden-
tify this subset of patients to reserve this relatively costly 
treatment to responsive patients and prevent unnecessary 
side effects in others.
Vascular endothelial growth factor (VEGF), the molecu-
lar target of Bv, was previously seen as an obvious predic-
tive marker of response to Bv. However, most studies in 
gliomas as well as in other pathologies have failed to show 
a correlation between a high level of VEGF detected in the 
circulation or in the tumour and outcomes of patients [5, 
6]. Other studies aimed at identifying a link between the 
molecular profile of the tumour and the response to Bv-
containing regimen. Patients from the BELOB trial with an 
initial tumour assigned to the specific molecular subtype of 
glioma, IGS-18, or classical GBMs, showed more benefit 
from Bv/CCNU treatment. This benefit was not found for 
patients treated with Bv only [7]. In a smaller retrospective 
cohort of patients treated at recurrence with a combination 
of Bv and irinotecan, patients with initial tumours assigned 
to IGS-18 or classical GBMs had, on the contrary, worse 
outcomes than those assigned to IGS-22/23 [8]. A micro-
RNA profile of tumour tissue has been described to have 
a predictive potential in GBM patients treated with Bv [9]. 
Differential expression of single genes, as angiotensino-
gen and HLA class II, has also been reported to predict Bv 
response in recurrent patients treated with the same com-
bined treatment [10]. A major limitation of these studies is 
the use of primary tumour tissue for classification/analysis, 
whereas the treatment targets the recurrent tumour. As the 
recurrent tumour is rarely available for GBM patients, look-
ing for blood biomarkers may be a better alternative.
In this study, we analysed different blood circulating 
immune cells at the time of relapse. Infiltrating immune 
cells are recognised to play a crucial role in regulating the 
formation and the remodelling of tumoural blood vessels 
and can regulate responsiveness and resistance to antiangi-
ogenic therapies [11]. The great majority of these cells are 
bone marrow-derived cells recruited to the tumour via the 
blood. Our hypothesis was that the inhibition of angiogen-
esis at the tumour level, following the blockade of VEGF 
by Bv, would lead to changes in the recruitment of immune 
cells, inducing variations in their peripheral levels. A first 
goal was to conduct a longitudinal follow-up of different 
subsets of immune cells in the peripheral blood of recur-
rent GBM patients during their course of Bv treatment. A 
second goal was to analyse the potential prognostic value 
of enumeration of these cells. To achieve this goal, we 
conducted a prospective clinical trial, in which patients 
were treated at relapse by Bv alone. Some of the results 
were further validated in two independent retrospective 
cohorts of GBM patients.
Materials and methods
Patients and study design
Initial prospective cohort
Recurrent GBM patients for whom a Bv treatment was 
planned as part of their care were enrolled in this bicen-
tric prospective study. The primary goal of the study was 
to perform a longitudinal follow-up of different circulat-
ing immune cells and to highlight those whose rates varied 
significantly during the course of treatment. The secondary 
goal was to search for a link between immune cell levels 
and overall patient survival. Patients were above the age of 
18 years, had a proven progressive disease occurring at least 
3 months after radiotherapy and 4 weeks after chemotherapy 
(if appropriate) and were eligible for a Bv treatment. After 
inclusion, they were treated with Bv 10 mg/kg i.v. every 
2 weeks until progression.
Validation cohorts
GBM patients treated at first recurrence with Bv alone or 
in association with camptothecin or nitrosoureas (cohort 1) 
or nitrosoureas alone (cohort 2) and for whom a complete 
blood count was available before treatment were selected.
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Analysis of blood samples
Fifteen millilitres of peripheral venous blood was collected 
in K2 EDTA tubes before initiation of Bv and then before 
the third, fifth and seventh cycles of treatment. The flow-
chart of the study design is illustrated in Sup. Figure 1. For 
each point, a complete blood cell count (CBC) was per-
formed on a Beckman Coulter haematology analyser. A 
six-colour flow cytometric analysis on fresh blood was also 
performed using a BD FACSCanto II cytometer (Rennes) 
or a Beckman cytometer (Paris). Flow cytometry analyses 
were performed using FACSDiva (BD Biosciences) and 
Kaluza (Beckman Coulter) software. The gating strategies 
are described in detail in Figure S2. Negative controls were 
included for defining accurate gating. Preliminary tests made 
it possible to ensure that identical results were obtained at 
the two sites carrying out the analysis. G-MDSCs (granu-
locytic myeloid-derived suppressor cells) were identified as 
 CD33+/CD203−/CD14−/CD16−/low/HLA-DR−. Classical, 
intermediate and non-classical monocytes were identified 
as  CD14high/CD16−,  CD14high/CD16+ and  CD14low/CD16+, 
respectively. Tie 2 expressing monocytes (TEM) were iden-
tified as  CD14+/Tie2+, M-MDSCs (monocytic myeloid-
derived suppressor cells) as  CD14+/HLA-DR−/neg and Treg 
as  CD3+/CD4+/CD25high/FoxP3+. VEGFR1 expression was 
analysed on  CD14+ cells and total leucocytes (cytometric 
analysis based on cell size and granularity). For each popu-
lation, an absolute number was calculated as follows: (total 
white blood cell count × percent of the population of interest 
among leucocytes)/100. For Treg, the percentage of Treg 
among  CD3+ T cells and among  CD3+/CD4+ T cells was 
also determined. For a detailed description of the antibodies, 
the methods used for labelling and the gating strategies, see 
Sup. Figure 2.
For the validation cohorts, data were extracted from CBC 
done as part of the standard monitoring of the patients.
Statistical analysis
Data were described using median [minimum–maximum] 
values concerning quantitative variables and frequencies 
n (%) for categorical variables. Biological counts were 
reported in the form of cell counts and percent out of cell 
populations of interest (e.g. % of Treg among  CD3+ T cells). 
Box plots were presented to draw evolution of biological 
counts at each sample time: before C1 (the first cycle noted 
C1), C3, C5 and C7. Evolution over time of the cell popula-
tions was tested through one-way ANOVA with repeated 
measures. Further pairwise comparisons from the baseline 
value (C1) were conducted with Wilcoxon matched pairs 
signed-ranks tests. No adjustment for alpha risk inflation was 
performed, but figure presentation allows reproducing such 
kind of reasoning by distinguishing p < 0.5, 0.01 and 0.001.
Overall survival was defined as the time between inclu-
sion in the study and death. Survival rates were estimated 
by the Kaplan–Meier method and survival curves compared 
by log-rank tests. Each explanatory factor was dichotomised 
by the median value at C1 and the median value of the ratio 
to baseline after two cycles (C3). Survival medians and 
95% confidence intervals are presented as M [95% IC lower 
bound–95% IC upper bound].
Results from the prospective cohort were then con-
firmed on two different historical cohorts of patients having 
received Bv (n = 61) or not (n = 27) at recurrence. Steroid 
intake at recurrence, neutrophil counts (> median) and inter-
actions between biological parameters and steroid intake 
were introduced in a multivariable Cox model.
Analysis was conducted with the R Core Team software 
(2014): a language and environment for statistical comput-
ing. R foundation for statistical computing, Vienna, Austria 
(http://www.R-proje ct.org/).
Results
Studied populations
Twenty-nine patients (21 in Rennes and 8 in Paris) were 
enrolled in the prospective study from September 2012 
through December 2014. The median overall survival was 
8.5 months [6.8–18.4]. To constitute the validation cohort 
1, all the GBM patients having received Bv at recurrence, 
not having participated in the prospective protocol and for 
whom a total blood count was available within 10 days 
before the start of treatment were extracted from the local 
database. Sixty-one patients treated between December 2008 
and May 2017 were selected. Among this cohort, 60% of 
patients received Bv alone as a second-line treatment and 
56% received a combined treatment (Bv and chemotherapy) 
as a second or third line. In the prospective cohort, half of 
the patients received a combined treatment (Bv and chemo-
therapy) after failure of Bv as monotherapy, which makes 
these two cohorts relatively similar. The validation cohort 
2 included 27 patients treated by nitrosourea alone between 
the dates of April 2009 and October 2015. The medians for 
overall survival were 8 months [6–11] and 9 months [5–17] 
for cohorts 1 and 2, respectively. Clinical patient character-
istics are summarised in Table 1.
Levels of different immune cells vary significantly 
during Bv treatment
As shown in Fig. 1, significant variations were recorded for 
total leucocytes during treatment, with a notable increase 
between the samples taken before treatment (5.8  G/L 
[2.3–14.2]) and the one taken before the third cycle (7.3 G/L 
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[3.8–14.9]) (p = 0.001). This increase was mainly due to the 
contingent of myeloid cells. Indeed, a similar profile was 
observed with neutrophils (3.9 G/L [1.54–13.35]) at C1, 
(5.5 G/L [2.45–14.71]) and C3 (p = 0.022) and with mono-
cytes (0.42 G/L [0.03–0.77]) at C1 (0.5 G/L [0.20–0.91]) 
and C3 (p = 0.005), whereas lymphocyte levels remained sta-
ble during the treatment. Among the monocytes, the increase 
was in the large majority population of classical monocytes. 
The absolute  CD3+CD4+CD25+FOXP3+ Treg count did not 
change during the course of treatment, whereas a decrease 
in the percentage of Treg among  CD3+ T cells and  CD3+/
CD4+T cells was observed with 2.26% and 4.325% at base-
line and 1.86% and 3.265% at C7, respectively (p = 0.016 
and 0.006). No significant variation was observed for the 
other analysed immune cells when considered as a per-
centage among leucocytes (for monocytes and MDSCs) or 
among  CD14+ cells (for monocytes).
Basal neutrophil and Treg counts have the best 
prognostic values for overall survival
For each cell population, the prognostic impact of the base-
line level and the ratio to baseline level after two cycles of 
treatment were tested. As shown in Table 2, a high baseline 
level (above the median) of total leucocytes, neutrophils and 
platelets had a significant pejorative impact on overall sur-
vival. Conversely, a high baseline level (above the median) 
of intermediate monocytes, non-classical monocytes and 
Treg had a positive impact on overall survival. The two 
best predictors of survival in our series of patients treated 
with Bv were the basal levels of neutrophils and Treg. No 
prognostic impact was found for the ratio to baseline level 
after two cycles of treatment. Figure 2 presents the plots of 
Kaplan–Meier survival curves showing the overall survival 
of patients dichotomised according to the median values. 
Patients with an absolute neutrophil count above 3.9 G/L had 
a median overall survival of 5.4 months [3.9–14.5], whereas 
patients with neutrophils below or equal to 3.9 G/L had a 
median overall survival of 17.5 months [8.5-NR] (p = 0.004). 
Patients with an absolute Treg count above 0.011  G/L 
had a median overall survival of 19.9 months [17.5-NR], 
whereas others had a median overall survival of 5.6 months 
[5.3–12.3] (p < 0.001).
Among clinical variables available, age was not a prog-
nostic variable, when baseline corticosteroid treatment 
was associated with reduced survival in univariate analy-
sis (p < 0.001). Unlike neutrophils, Treg had a prognostic 
impact regardless of steroid in bivariate analysis (Table 3).
Neutrophil count has a high positive predictive 
value of response to Bv, only in steroid‑free patients
Treg results could not be validated in retrospective data as it 
requires flow cytometry that is not routinely performed. On 
the contrary, this could be done in two independent cohorts 
for neutrophil counts, using the previously determined cut-
off 3.9 G/L. In the cohort of 61 patients treated at recur-
rence with Bv with or without chemotherapy, the results 
were similar to those obtained during the prospective trial. 
Patients with an absolute neutrophil count above 3.9 G/L 
had a median overall survival of 6 months [5–10], whereas 
patients below 3.9 G/L had a median overall survival of 
16 months [8-NR] (p < 0.001) (Fig. 3a). On the other hand, 
Impact on overall survival of neutrophils was not found in 
the cohort of 26 patients treated at recurrence with nitros-
ourea alone (Fig. 3b). This indicates that neutrophil count is 
predictive of response to Bv in GBM patients at recurrence.
As observed in the prospective cohort, age was not a 
prognostic variable (data not shown), when baseline corti-
costeroid treatment was associated with reduced survival in 
univariate analysis (p = 0.001) (Table 3). On the other hand, 
both corticosteroids and neutrophils remained significant in 
bivariate analysis, with a positive interaction between these 
two variables (p = 0.024) (Table 3).
The neutrophil count was 3.3 G/L [2.1–8.2] in the popula-
tion that did not take corticosteroids at the beginning of Bv 
Table 1  Baseline characteristics 
of the patients
Bv bevacizumab, CT chemotherapy, PFS progression-free survival, OS overall survival
Prospective cohort 
(n = 29)
Validation cohort 1
Bv+/− CT (n = 61)
Validation 
cohort 2
CT only (n = 27)
Age (years)
 Median 59.1 56.9 59.9
 Range (32–76) (31–79) (37–81)
Use of glucocorticoids [n (%)]
 No 13 (45%) 18 (30%) 13 (48%)
 Yes 16 (55%) 43 (70%) 14 (52%)
Median survival (months)
 OS 8.5 8.0 9.0
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treatment compared to 7.4 G/L [2.1–15.1] for the patients 
on corticosteroids (p = 1.4 × 10−5, Wilcoxon test) (Fig. 3c). 
It should be noted that among the 18 patients without cor-
ticosteroids at baseline treatment, 11 had received no cor-
ticosteroids during their previous postoperative treatment 
and could therefore be considered ‘glucocorticoid-naïve’. 
After stratification of patients according to corticosteroid 
treatment, predictive value of neutrophil count remained sig-
nificant only in the population without corticosteroid intake 
at recurrence (n = 18), resulting in a better overall survival 
for patients with low neutrophils counts of 41 months [16-
NR], compared to 7.5 months [5-NR] for patients with high 
neutrophil counts (p = 0.007) (Fig. 3d, e).
Discussion
In this study, we were able to show that different popula-
tions of circulating cells vary significantly in GBM patients 
treated at recurrence with Bv, especially with an increase in 
the absolute number of different subsets of myeloid cells that 
occurs after the first two cycles of treatment. The only sig-
nificant observed reduction was for the percentage of Treg 
among  CD3+ or  CD3+/CD4+ T cells. A similar reduction in 
blood Treg percentage, linked to a decrease in their prolif-
eration, has been reported for metastatic colorectal cancer 
after two cycles of Bv plus chemotherapy [12]. In our cohort 
of patients, this decrease had no impact on patients’ behav-
iour, whereas it correlates with a better overall survival in 
metastatic renal cancer patients treated with sunitinib, a mul-
titargeted receptor tyrosine kinase inhibitor (TKI) includ-
ing VEGFR types 1 and 2 [13]. In GBM patients treated at 
recurrence with axitinib, a selective inhibitor of VEGFR-1, 2 
and 3, a significant increase of the percentage of Treg within 
 CD4+ T cell was observed after 6 weeks of treatment in the 
case of progressive disease [14].
The best correlations with survival, in our prospective 
cohort of patients, were found for factors analysed before 
treatment, not for decrease or increase of a particular subset 
of immune cells. It seems therefore that the pre-existing state 
of the patient conditions the response to treatment, rather 
than the specific activity of Bv on the different immune cells 
analysed. More than half of the patients were receiving corti-
costeroids before the introduction of Bv at recurrence, which 
indicates that they had neurologic symptoms. These patients 
had a shorter survival, which could be linked to a poorer 
performance status and/or a greater tumour volume. One 
cannot also exclude a direct deleterious effect of corticoster-
oids. Retrospective clinical analyses have indeed identified 
corticosteroid use during first-line radiotherapy as an inde-
pendent indicator of shorter survival in three independent 
cohorts of GBM patients [15].
Patients receiving corticoids had higher neutrophil counts 
than steroid-independent patients. This is a well-known 
effect of corticosteroid intake, due in particular to their 
demargination from the endovascular lining of the blood 
vessels [16], which can explain why the prognostic value 
of neutrophil count was lost for these patients. On the other 
hand, the basal neutrophil count refined the prognosis among 
patients without corticosteroids, with the identification of 
patients with a particularly long median survival of 3.4 years 
from the beginning of Bv treatment.
Neutrophils are the most abundant white blood cells in 
humans. It has now been well established that these cells 
are not only terminally differentiated involved in infection, 
but can also be found in different stages of maturation and 
activation into the blood from which they can extravasate 
into tissues. Especially, a population of circulating  CD49d+/
VEGFR1high/CXCR4high neutrophils that stimulates angio-
genesis has been described in humans and mice. These 
neutrophils represent a small population in healthy humans 
and are recruited to tissue by VEGF-A [17]. Glioma models 
suggest that increased recruitment of neutrophils during anti-
VEGF therapy promotes glioma progression with a mes-
enchymal switch and may promote tumour resistance [18]. 
Neutrophils may also be involved in immunosuppression. 
In GBM patients, an expanded population of circulating 
degranulated neutrophils characterised by a decrease in den-
sity and an increase of arginase release inducing a peripheral 
immunosuppression has been described [19]. These neutro-
phils could correspond to the recently described immuno-
suppressive neutrophils, characterised by the expression of 
CD10+ that can inhibit proliferation and interferon gamma 
production by T cells via a CD18-mediated contact-depend-
ent arginase 1 release [20]. It would certainly be interesting 
to distinguish these different neutrophil subtypes in GBM 
patients using these new markers.
MDSCs are also myeloid cells frequently described as 
involved in GBM immunosuppression. These cells are a 
heterogeneous population of cells at different stages of dif-
ferentiation. At least two distinct MDSC subpopulations 
have been identified in humans: the granulocytic subset 
(G-MDSCs) and the monocytic subset (M-MDSCs). An 
increased number of both types of circulating MDSCs has 
been reported in the PBMC (peripheral blood mononuclear 
cells) of GBM patients compared to normal donors [21, 22]. 
The number of MDSCs remains, however, relatively low 
compared to neutrophils, with an average of 40 neutrophils 
for one MDSC in our study. Furthermore, we show here that 
the number of MDSCs does not vary significantly during Bv 
treatment and does not correlate with patient survival.
A pre-treatment neutrophil–lymphocyte ratio (NLR) 
has been shown to be prognostic in several solid tumours. 
For newly diagnosed GBM patients treated according to 
the Stupp protocol, no less than four studies have reported 
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that a high ratio (4.1–7.5, depending on the study) before 
treatment is correlated with a shorter survival [23–26]. This 
ratio is regarded as a marker of systemic cancer-associated 
inflammation. In our prospective cohort, we observed that 
a median basal NLR of 5.2 and patients with a value above 
the median had no significant shorter median overall sur-
vival (7.2 months versus 17.5 months; p = 0.083, data not 
shown). However, a prognostic value was obtained when 
considering the neutrophil count alone. Such an association 
between blood baseline neutrophil count and Bv efficacy in 
GBM has previously been reported, but with contradictory 
results as compared with ours. In the retrospective cohort 
reported in the study of Bertaut et al. [27], GBM patients 
Fig. 1  Immune cells with significant variations during bevacizumab 
treatment. A complete blood cell count (CBC) and a cytometric anal-
ysis were assessed at baseline (C1) and before the third (C3), the fifth 
(C5) and the seventh (C7) cycles of treatment. Leucocyte, neutrophil, 
eosinophil, total monocyte and classical monocyte counts increased, 
whereas percentage of Treg among  CD3+ and  CD3+/CD4+ T cells 
decreased during treatment. The bottom of the box-and-whisker plot 
graph shows the 25th percentile of the variable, the line within the 
box indicates the median, and the top of the box shows the 75th per-
centile. Ends of the whiskers are at 25th percentile − (1.5 × interquar-
tile range) and 75th percentile + (1.5 × interquartile range). Outliers 
are indicated as small circles. † indicates p values for global change 
during treatment (p ≤ 0.05†, p ≤ 0.01††, one-way repeated ANOVA). * 
indicates p values for changes between baseline and the subsequent 
cycles (p ≤ 0.05*, p ≤ 0.01**, p ≤ 0.001***, Wilcoxon test)
◂ Table 2  Cell populations with a prognostic impact on overall survival
Patients were dichotomised according to the median value of the 
different cell populations. Comparison of survival curves was done 
using the log rank test. Populations with a negative impact on sur-
vival appear on bold
CBC complete blood cell count, FCM flow cytometry
Cell population Baseline level
Cutoff (G/L) p
Total leucocytes (CBC) 5.8 0.01
Neutrophils (CBC) 3.9 0.004
Platelets (CBC) 189 0.022
Intermediate monocytes (FCM) 0.023 0.026
Non-classical monocytes (FCM) 0.013 0.027
Treg (FCM) 0.011 < 0.001
Fig. 2  Overall survival for 
the initial cohort of patients. 
Kaplan–Meier analysis of 
overall survival according to 
basal neutrophil (a) and Treg 
(b) counts
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were treated mostly with radio-chemotherapy as a first-line 
and 60% of them received a Bv-based regimen at recurrence. 
Neutrophil count was performed before the initiation of the 
first treatment and overall survival was calculated from 
the date when therapy started to the date of death. In the 
whole cohort of patients, a high neutrophil count (> 6 G/L) 
was associated with poorer survival, but this association 
remained only in the group of patients not receiving Bv. 
The authors concluded that Bv was able to counterbal-
ance the deleterious effect of a high neutrophil count. In 
this study, overall survival was the result of the initial treat-
ment, comprising temozolomide (TMZ) and the treatment 
at recurrence, with or without Bv. In this case, the status 
of  O6-methylguanine DNA methyltransferase (MGMT) pro-
moter methylation, which is a very powerful predictor of 
response to TMZ for newly diagnosed GBM patients, with a 
PFS difference of approximately 7 months between “methyl-
ated” and “unmethylated” patients, [28] should have been 
taken into account. However, this was not the case and could 
have induced a bias in the reported result. On the other hand, 
given the significant fluctuations in neutrophil counts, espe-
cially those induced by corticosteroid treatment, it seems 
preferable to consider the neutrophil count at the beginning 
of Bv treatment, as was done in our study. In any case, only 
complementary prospective studies will allow the validation, 
or not, of these different results.
Another potential interesting biomarker associated with 
overall survival in our prospective cohort of patients was 
the basal absolute count of Treg. As Treg contribute to 
immunosuppressive mechanisms, high levels of these cells 
are intuitively expected to correlate with a poor prognosis. 
However, if a high tumour infiltration by Treg is signifi-
cantly associated with shorter overall survival in many solid 
tumours, the opposite can be observed [29–31]. In GBM, 
in particular, some studies have shown a prognostic value 
of  Foxp3+ tumour-infiltrating lymphocytes [32], and others 
not [33, 34]. In any case, lymphocytes and especially Treg 
remain a minority contingent of immune cells in GBM 
tumours compared to myeloid cells. Concerning the prog-
nostic impact of peripheral blood Treg, the same phenome-
non can be observed. For example, in patients with follicular 
lymphoma, high levels prior to therapy have been associated 
with decreased PFS [35]. On the other hand, no correlation 
was observed between the pre-treatment percentage of circu-
lating Treg and survival in newly diagnosed GBM patients, 
[33] whereas in diffuse large B-cell lymphoma (DLBCL), a 
low number of circulating Treg has been shown to be asso-
ciated with poor prognosis [36]. The prognostic value of 
Treg seems to vary according to the type of tumour, but also 
according to the treatment. We have also to keep in mind that 
Treg are not a homogeneous population. Different stages of 
activation/differentiation have been described based on the 
expression of markers, such as CD127/CD152/CD45RO. In 
patients with non-small cell lung cancer (NSCLC) treated 
with front-line chemotherapy, an increased percentage of 
baseline naive Treg is associated with a poor clinical out-
come, whereas high baseline levels of terminal effector Treg 
Table 3  Univariate and 
bivariate survival analysis
HR hazard ratio, CI confidence interval
Univariate analysis Bivariate analysis
HR (95% CI) p value HR (95% CI) p value
Prospective cohort (Bv)
 Corticosteroid use (yes) 4.8 [1.90; 12.12] < 0.001 3.7 [1.31; 10.22] 0.013
 Neutrophil count > 3.9 G/L 3.31 [1.43; 7.65] 0.005 1.96 [0.76; 5.05] 0.164
Prospective cohort (Bv)
 Corticosteroid use (yes) 4.8 [1.90; 12.12] < 0.001 2.1 [0.65; 6.96] 0.212
 Treg count > 0.011 G/L 0.13 [0.04; 0.40] < 0.001 0.21 [0.05; 0.83] 0.026
Validation cohort 1 (Bv+/− CT)
 Corticosteroid use (yes) 3.2 [1.58; 6.56] 0.001 7.2 [1.84; 27.94] 0.005
 Neutrophil count > 3.9 G/L 3.2 [1.55; 6.80] 0.002 5.9 [1.63; 21.61] 0.007
 Interaction – – 0.16 [0.03; 0.78] 0.024
Fig. 3  Overall survival for the validation cohorts and impact of corti-
costeroid intake. Kaplan–Meier analysis of overall survival according 
to basal neutrophil in a series of 61 glioblastoma patients treated at 
recurrence with bevacizumab alone or with chemotherapy (a) and in 
a series of 26 glioblastoma patients treated at recurrence with nitro-
soureas (b). c Impact of corticosteroid intake on neutrophil count 
in the series of 61 patients. The bottom of the box-and-whisker plot 
graph shows the 25th percentile of the variable, the line within the 
box indicates the median and the top of the box shows the 75th per-
centile. The ends of the whiskers are at 25th percentile − (1.5 × inter-
quartile range) and 75th percentile + (1.5 × interquartile range). Outli-
ers are indicated by small circles. **** indicates the p value of the 
neutrophil counts of patients taking corticosteroids versus those not 
taking corticosteroids (p = 1.3 × 10−7, calculated by t test). Kaplan–
Meier analysis of overall survival according to basal neutrophil count 
in patients without corticosteroids (c) or with corticosteroids (d) and 
receiving a bevacizumab containing regimen
◂
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is correlated with improved clinical response [37]. As for 
neutrophils, it would therefore be interesting to check if 
peripheral Tregs found in GBM patients at recurrence dis-
play a particular activation profile. In our prospective cohort 
of patients exclusively treated at recurrence with Bv, a high 
level of Treg, defined as  CD3+CD4+CD25+FOXP3+, was 
linked to a better prognosis. In contrast to neutrophils, Treg 
levels and their prognostic significance were not influenced 
by corticosteroid use. This could be regarded as an advan-
tage for using Treg as a prognostic marker instead of neutro-
phils. However, we believe that neutrophils respond better 
to the quality criteria required for a good biomarker, such as 
robustness, reproducibility and accessibility.
The overall survival observed in our two cohorts of 
patients treated at recurrence with Bv are consistent with 
those reported in the literature [38]. However, to our knowl-
edge, no biomarker to date has identified a population with 
such a long median survival. In the study of Tabouret et al., 
for example, high plasma matrix metalloproteinase-2 levels 
in recurrent HGG receiving Bv were associated with a better 
overall survival of 12.8 months, [39] compared to 41 months 
for corticosteroid-free patients with a low neutrophil count 
in our validation cohort. Of course, this difference could be 
due to the selection bias of patients likely to receive Bv at 
the phase of relapse. Nevertheless, we believe that these new 
criteria (neutrophil count and corticosteroid intake) should 
be tested in the large clinical studies previously reported that 
have used Bv in GBM at relapse and could easily be entered 
into the current practice of oncologists.
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